Skip to content
Open access

Pharmacoresistant epilepsy associated with genetic variants in SYNGAP1 and SCN2A with clinical response to cannabidiol: a case report

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: A 7-year-old girl, born at term without perinatal complications, presented with global developmental delay and epilepsy onset at 6 months of age, characterized by absence and atonic seizures. The patient experienced more than 50 seizures per day, with frequent sudden falls due to hypotonia. Hypotonia had been present since early infancy and was associated with motor developmental delay. Brain magnetic resonance imaging and metabolic investigations showed no abnormalities. The patient evolved with pharmacoresistant epilepsy, with no response to multiple antiseizure medications (levetiracetam, valproic acid, phenobarbital, and clobazam). At 3 years of age, whole-exome sequencing identified a heterozygous pathogenic variant in the SYNGAP1 gene (c.2578_2579del; p.Val860Phefs*77) and a variant in the SCN2A gene, both associated with Developmental and Epileptic Encephalopathies (DEE). After introduction of clonazepam and cannabidiol (20 mg/kg/day), a marked reduction in seizure frequency was observed, including seizure-free days, along with improvement in falls, behavior and social interaction. Discussion: The syndrome associated with the SYNGAP1 gene is a developmental and epileptic encephalopathy frequently caused by truncating variants leading to loss of gene function. Epilepsy occurs in approximately 80–90% of affected individuals and typically manifests with absence and myoclonic seizures, often showing pharmacoresistance. The SCN2A gene is also associated with developmental and epileptic encephalopathies and may present with early-onset epilepsy, neurodevelopmental delay and pharmacoresistant seizures. The coexistence of variants in genes involved in synaptic function (SYNGAP1) and neuronal excitability mediated by sodium channels (SCN2A) may modulate the severity of the epileptic phenotype. The high daily seizure burden observed in this patient is consistent with phenotypes described in these genetic encephalopathies. No disease-specific therapeutic protocol has been established and responses to antiseizure medications remain variable. Cannabidiol has been increasingly used in refractory genetic epilepsies; however, data addressing SYNGAP1 and SCN2A variants remain limited. In this case, seizure frequency markedly decreased, with seizure-free days and significant functional improvement, suggesting benefit of cannabidiol as adjunctive therapy. Final Comments: This case represents a rare genetic condition associated with developmental and epileptic encephalopathies. Variants in SYNGAP1 and SCN2A are associated with developmental delay, intellectual disability and frequently pharmacoresistant epilepsy. Identification of these variants through whole-exome sequencing is essential for diagnostic clarification and improved understanding of the clinical phenotype. In this patient, the marked response to cannabidiol highlights its potential role as adjunctive therapy in refractory genetic epilepsies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.